english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Ivacaftor + tezacaftor + elexacaftor (Kaftrio°) in cystic fibrosis with at least one F508del mutation: respiratory symptoms alleviated in the short term

FEATURED REVIEW Is this triple therapy more effective than dual therapy at reducing the incidence of pulmonary exacerbations and alleviating symptoms? Does it slow disease progression and extend survival? What adverse effects are associated with the addition of elexacaftor?
Full review (4 pages) available for download by subscribers.
1 March 2022

In the March issue of Prescrire International: Revision of European pharmaceuticals legislation

FREE DOWNLOAD Prescrire has responded to a public consultation on a planned revision of Directive 2001/83 "on the Community code relating to medicinal products" and Regulation 726/2004 "laying down Community procedures for the authorisation and supervision of medicinal products (...) and establishing a European Medicines Agency".
Full text available for free download.
1 March 2022

Rational deprescribing

 Editorial  The term "deprescribing" has been used more and more in recent years. But deprescribing, like prescribing, is not without risk.
1 March 2022

The Prescrire Awards for 2021: two "Pilule d'Or" Awards, and 5 drugs on the "Honours List". Details in the March issue of Prescrire International

ThePrescrire Awards independent French medical journal Prescrire conferred two "Pilule d'Or" ("Golden Pill") Awards for 2021; 5 drugs made the "Honours List", and 2 drugs were deemed "Noteworthy". Details for the Drug and Information Awards, published in the March issue of Prescrire International, are available HERE.
1 March 2022

Tramadol: achieving successful withdrawal after prolonged use

Tramadol, an opioid analgesic authorised for relief of moderate to severe pain, carries a risk of dependence. Discontinuation is sometimes difficult and can require strong patient motivation as well as long-term medical support.
1 March 2022

Benzodiazepines: risk of persistent use even after brief treatment

Occasional benzodiazepine use is often followed by repeated use, and there is a risk of addiction. When a benzodiazepine is justified, it is important to plan its withdrawal, together with the patient, as soon as treatment starts.
1 March 2022

Prescrire publishes its annual update of drugs to avoid, in the name of better patient care

Drugs to avoid  DRUGS TO AVOID - 2022 UPDATE  For the tenth consecutive year, independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to  prevent disproportionate harm to patients
1 February 2022

Myocarditis linked to the covid-19 messenger RNA vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°): an update

FEATURED REVIEW A number of peer-­reviewed articles and drug regulatory agency reports have been published around the world about cases of myocarditis attributed to the covid­-19 messenger RNA vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°). What is known about the incidence, severity and risk factors for this adverse effect?
Full review (2 pages) available for download by subscribers.
1 February 2022

In the February issue of Prescrire International: Rituximab (Mabthera° or other brands) in certain non-Hodgkin lymphomas in children

FREE DOWNLOAD In the "Marketing Authorisations" section of the February issue: what do Prescrire's editors make of the data regarding this new indication for rituximab?
Full text available for free download.
1 February 2022

Covid-19 vaccines: good for business too

 Editorial  The speed with which effective vaccines were developed to combat the covid-19 pandemic was astonishing. And the speed with which certain drug companies have reaped enormous profits has been equally spectacular.
1 February 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90